ZOLINZA

This brand name is authorized in Australia, Canada, Japan, Mexico, United States

Active ingredients

The drug ZOLINZA contains one active pharmaceutical ingredient (API):

1 Vorinostat UNII 58IFB293JI - VORINOSTAT

Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Read about Vorinostat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZOLINZA Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XH01	Vorinostat	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors
Discover more medicines within L01XH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11138F, 11141J
Country: CA	Health Products and Food Branch	Identifier(s): 02327619
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291025M1029
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 063M2010
Country: US	FDA, National Drug Code	Identifier(s): 0006-0568